Fig. 2: Efficacy evaluation. | Nature Communications

Fig. 2: Efficacy evaluation.

From: Nivolumab plus anlotinib hydrochloride in advanced gastric adenocarcinoma and esophageal squamous cell carcinoma: the phase II OASIS trial

Fig. 2

A Waterfall plot of the best percentage change in target lesion diameter from baseline within the efficacy-evaluable population (n = 48). Tumor measurements and response evaluations were performed according to irRECIST. B Spider plot of tumor burden changes from baseline within the efficacy-evaluable population (n = 48). C Swimmer plot of treatment durations and survival (n = 48). Each bar represents one patient. D Kaplan–Meier curve of progression-free survival (PFS) in the full analysis set of the 48 patients. The median PFS was 4.0 months. Shaded areas represent 95% confidence intervals. E Kaplan–Meier curve of overall survival (OS) in the full analysis set of the 48 patients. The median OS was 11.1 months. Shaded areas represent 95% confidence intervals. CR Complete Response; PR Partial Response; SD Stable Disease; PD Progression Disease.

Back to article page